Aging is Soon to Be a Preventable Disease

Medicine has always framed its highest obligation as responding to suffering. But the greatest failure of modern healthcare may not be how we treat disease, it is how confidently we wait for it to arrive.

The reactive trap

Modern medicine operates under the “do no harm” principle. In practice, this means that physicians will only advise treatment or intervention when there is clear evidence of existing pathology. Without a diagnostic code, there is no treatment. Without a symptom, there is no concern. The result is a system more accurately described as sick-care than healthcare: it waits for disease to arrive, then responds.

The consequences of this reactive stance are profound. According to NIH’s National Center for Advancing Translational Sciences, of the thousands of diseases that affect humans, only approximately 500 have any FDA-approved treatment. Today, less than 22% of the world’s recognized diseases have approved therapies, and over 95% of rare diseases have no treatment at all. Non-communicable diseases, the chronic, slow-moving conditions most shaped by aging, kill more than 43 million people annually, accounting for 75% of all non-pandemic-related deaths globally. Many of these deaths are not sudden. They are the end of a decades-long slide that the healthcare system watched, largely without intervening, until it was too late.

A model that already works

Prevention is not a theoretical aspiration. It is a proven strategy, one we already apply to the most vulnerable patients we have.

By the late 1940s, vaccines against diphtheria, tetanus, and pertussis were being routinely recommended for infants and children in the United States. The polio vaccine, licensed in 1955, eliminated a disease that had been paralyzing thousands of children each year. Today, the US childhood immunization schedule protects against more than 16 diseases, and the CDC estimates that among children born between 1994 and 2023, routine vaccination prevented approximately 508 million cases of disease, 32 million hospitalizations, and more than 1.1 million premature deaths. Every one of those vaccinations was administered to a healthy child who had no symptoms, no diagnosis, and no pathology, because we decided the evidence justified acting before the disease arrived.

That is prevention working exactly as it should. The same logic applies to aging, and the biology is now telling us that the window to apply it exists.

The biology has moved

For most of human history, cellular aging was treated as biologically fixed, an inevitable accumulation of damage with no meaningful pathway to reversal. That assumption is no longer tenable.

Yamanaka’s Nobel Prize-winning discovery that mature adult cells could be reprogrammed back to an induced pluripotent stem cell state was the first hard evidence that cellular age is not a one-way street. Since then, partial reprogramming, pulsing Yamanaka factors just long enough to reset epigenetic age without fully dedifferentiating the cell, has demonstrated the ability to reverse multiple hallmarks of aging: epigenetic drift, mitochondrial dysfunction, inflammatory gene expression, and telomere-associated markers, across multiple tissue types and model organisms. These are not marginal observations. They are systematic evidence that the biological machinery of aging can be run in reverse under the right conditions.

The honest addendum is this: we cannot yet do this reliably in clinical settings. iPSC-based reprogramming carries real risks, including teratoma formation and loss of cell identity if taken too far. Partial reprogramming sits on a narrow safety window that researchers are still mapping with precision. The point is not that clinical tools are ready today, it is that underlying biology has given us proof of concept, and translation work is underway. Biologically, aging damage can be prevented, slowed, and in targeted respects, reversed. Clinically, the daily practices and validated protocols to achieve this at scale do not yet exist.

A system built against prevention

Even if the tools were ready, a deeper structural problem would remain: the system that governs healthcare delivery is not built to reward prevention.

Under the dominant fee-for-service model, hospitals and providers are compensated per visit, per scan, per procedure. More interventions mean more revenue, which creates a natural incentive toward volume and treatment intensity once a patient is sick, including, in well-documented cases, low-value or unnecessary care. Patients and insurers, by contrast, have the precise opposite interest: they benefit most when people remain healthy, consume fewer services, and avoid expensive acute episodes entirely.

This is a structural misalignment, and it runs directly counter to what longevity medicine requires. The most powerful interventions for extending healthy lifespan are early ones, applied not at the point of diagnosed disease but years or decades before, when the biological return on investment is highest. A new cost framework is needed: one that factors in the full downstream value of prevention, including the hospitalizations that do not happen, the chronic disease management costs that never accumulate, and the productive years of life that are preserved. If a single preventive intervention can credibly add ten or twenty years of healthy lifespan, the comparative economics against a decade of managing the conditions that absence of prevention would produce are not complicated. They are strongly favorable, for the patient, and for the insurer.

What comes next

Longevity medicine is still early. Biology is running ahead of clinical tools, and clinical tools are running ahead of the regulatory and economic systems that would enable their adoption at scale. Just as where infectious disease stood before germ theory, where cardiovascular medicine stood before statins, where oncology stood before targeted therapy.

In the not-too-distant future, the cellular damage that drives aging will become a process that can be meaningfully prevented, slowed, and progressively reversed. The tools to do so are being built now.

Photo: Ridofranz, Getty Images

This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.